Navigating Complexity in Pulmonary Trials

We all arrive at clinical research by different paths.

For me, early work as a respiratory therapist and paramedic at several large academic institutions offered a firsthand view of clinical study teams and the patients they serve.

I delivered therapies to individuals living with conditions ranging from common obstructive diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma, to rarer restrictive and fibrotic diseases, including Idiopathic Pulmonary Fibrosis (IPF), Acute Respiratory Distress Syndrome (ARDS), and Cystic Fibrosis (CF).

Often, those treatments had an immediate impact on a patient’s quality of life. Seeing breathing become less labored, color return to a patient’s face, or oxygen levels improve helped inspire my work in drug development.

.

Understanding the Complexity

For Sponsors developing therapies in indications such as COPD, IPF, ARDS, or CF, studies can be especially challenging. Unpredictable disease progression, heterogeneous patient populations, and burdensome endpoints can make traditional trial models insufficient for capturing meaningful treatment effects.

Pulmonary diseases are clinically complex and often difficult to study. IPF involves progressive lung scarring, ARDS is characterized by acute inflammation and fluid buildup, and CF results from genetic mutations that cause thick mucus in the lungs.

While these conditions differ in cause and presentation, they share several trial design challenges, including unpredictable progression, high clinical variability, and endpoints that may not fully reflect how patients feel or function.

Why Traditional Trials Struggle

Fixed randomized controlled trials (RCTs) can struggle to capture meaningful signals in pulmonary studies. Variable disease trajectories, high dropout rates, and endpoints such as Forced Vital Capacity (FVC) or the 6-Minute Walk Test (6MWT) may limit interpretability.

As a result, trials may experience delays, protocol amendments, or inconclusive outcomes—not necessarily because a therapy lacks promise, but because the study design is not well aligned with the complexity of the disease.

Navigating the operational and scientific challenges of complex pulmonary trials can necessitate:

• Flexible protocols that account for disease variability
• Adaptive and enrichment strategies to improve signal detection
• Strategic endpoint selection and biomarker integration, and
• Strengthened patient retention through decentralized and patient-centric models.

Looking Ahead

With this in mind, I’ve put together a series on smarter trial designs for complex pulmonary diseases.

The articles within this series explore three strategies for improving pulmonary trials:

1. Adaptive trial designs,
2. Enrichment strategies, and
3. Biomarker-driven approaches.

Each article includes practical examples and shows how PharPoint can help Sponsors execute smarter, more responsive studies in complex pulmonary indications – all available now on our website, or available as a single download within the document below.